NVO
Novo Nordisk A/S
NVO
Meridian score28
QualityQuality: 20th percentile
MomentumMomentum: 34th percentile
GrowthGrowth: 11th percentile
ValuationValuation: 77th percentile
ExpectationsExpectations: 80th percentile
ResearchNot researched
Evidence to review
- Financial comparability: Goodwill and intangible assets increased materially; review acquisition effects.
Stage and trend
Stage 1 · BasingAbove 21d: noAbove 50d: noAbove 200d: no50d over 200d: no
Weeks in stage7 · week open
30-week lineRising
From 30-week line-11.3%
Price · Oct 27$38.67
From 52w high-36.8%
Relative volume0.6x
1M-0.1%
3M-24.1%
6M-4.9%